{"id":"naltrexone-pill","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL1201149","moleculeType":"Small molecule","molecularWeight":"377.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone competitively binds to opioid receptors (mu, delta, and kappa) in the central nervous system, preventing opioid agonists from activating these receptors. This mechanism reduces the rewarding effects of opioids and alcohol, thereby decreasing cravings and supporting abstinence. It is used in addiction medicine to support recovery from opioid use disorder and alcohol use disorder.","oneSentence":"Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for alcohol and opioids.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:46.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"},{"name":"Alcohol use disorder"}]},"trialDetails":[{"nctId":"NCT04599478","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-06-29","conditions":"Loss-of-control Eating, Obesity/Overweight","enrollment":160},{"nctId":"NCT07224009","phase":"PHASE2","title":"Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-03","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT04605081","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-01-10","conditions":"Loss-of-Control Eating, Obesity/Overweight","enrollment":100},{"nctId":"NCT07132177","phase":"PHASE2","title":"Targeted Naltrexone to Support Individuals Participating in Dry January","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-11-03","conditions":"Alcohol Misuse","enrollment":20},{"nctId":"NCT06374290","phase":"PHASE1","title":"Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-07-16","conditions":"Smoking Cessation","enrollment":2},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT05053503","phase":"NA","title":"Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"Spark Biomedical, Inc.","startDate":"2022-05-27","conditions":"Opioid-use Disorder, Opioid Withdrawal","enrollment":108},{"nctId":"NCT05157698","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-01-13","conditions":"Obesity","enrollment":160},{"nctId":"NCT02502162","phase":"NA","title":"Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome","status":"RECRUITING","sponsor":"Stanford University","startDate":"2015-06","conditions":"Complex Regional Pain Syndrome","enrollment":120},{"nctId":"NCT05827159","phase":"PHASE3","title":"Emergency Department-Initiated Medications for Alcohol Use Disorder","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-08-17","conditions":"Alcohol Use Disorder","enrollment":240},{"nctId":"NCT05007561","phase":"EARLY_PHASE1","title":"Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences","status":"RECRUITING","sponsor":"San Diego State University","startDate":"2021-11-16","conditions":"Naltrexone, Placebo","enrollment":210},{"nctId":"NCT05940324","phase":"PHASE2","title":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-02-24","conditions":"Obsessive-Compulsive Disorder","enrollment":150},{"nctId":"NCT03539900","phase":"PHASE2, PHASE3","title":"Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-04-17","conditions":"Binge-Eating Disorder","enrollment":89},{"nctId":"NCT05093296","phase":"PHASE2, PHASE3","title":"Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2021-12-02","conditions":"Alcohol Use Disorder, Alcoholism, Alcohol Addiction","enrollment":62},{"nctId":"NCT03047005","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-28","conditions":"Binge-Eating Disorder, Obesity","enrollment":68},{"nctId":"NCT04450316","phase":"PHASE2","title":"Low-dose Naltrexone for Bladder Pain Syndrome","status":"SUSPENDED","sponsor":"Stanford University","startDate":"2020-10-08","conditions":"Bladder Pain Syndrome, Interstitial Cystitis","enrollment":40},{"nctId":"NCT03852628","phase":"PHASE2","title":"Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD","status":"TERMINATED","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2019-05-20","conditions":"Post Traumatic Stress Disorder, Alcohol Abuse","enrollment":69},{"nctId":"NCT05037032","phase":"PHASE4","title":"Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude","status":"COMPLETED","sponsor":"VA Loma Linda Health Care System","startDate":"2021-08-08","conditions":"Altitude, Sleep Apnea, Central","enrollment":16},{"nctId":"NCT00271024","phase":"PHASE2","title":"Efficacy of Naltrexone in Women's Smoking Cessation","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2005-12","conditions":"Smoking, Smoking Cessation","enrollment":333},{"nctId":"NCT03045341","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-02-27","conditions":"Binge-eating Disorder, Obesity","enrollment":136},{"nctId":"NCT00775229","phase":"PHASE2","title":"Naltrexone in the Treatment of Trichotillomania","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2008-08","conditions":"Trichotillomania","enrollment":51},{"nctId":"NCT04270877","phase":"PHASE2","title":"Fibromyalgia and Naltrexone: The FINAL Study","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2021-01-06","conditions":"Fibromyalgia","enrollment":99},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT03970330","phase":"PHASE3","title":"Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-01-16","conditions":"Endometriosis","enrollment":9},{"nctId":"NCT00332605","phase":"PHASE2","title":"N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-06","conditions":"Methamphetamine Dependence","enrollment":45},{"nctId":"NCT02537197","phase":"PHASE1","title":"The Effect of Regular Naltrexone Dosing on Disordered Gamblers","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-04","conditions":"Gambling","enrollment":35},{"nctId":"NCT05228418","phase":"PHASE4","title":"Bridging ED to Outpatient AUD Therapy With Naltrexone","status":"UNKNOWN","sponsor":"Albert Einstein Healthcare Network","startDate":"2022-03","conditions":"Alcohol Use Disorder","enrollment":20},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT02137252","phase":"PHASE2","title":"Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-05","conditions":"Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ","enrollment":3},{"nctId":"NCT00142818","phase":"PHASE2","title":"Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2006-02","conditions":"Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders","enrollment":164},{"nctId":"NCT01893827","phase":"PHASE4","title":"Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06","conditions":"Alcohol Dependence","enrollment":237},{"nctId":"NCT04322526","phase":"PHASE4","title":"Study of Naltrexone-Induced Blockade of Antidepressant Effects","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2017-07-01","conditions":"Depression, Major Depressive Disorder","enrollment":25},{"nctId":"NCT04250792","phase":"PHASE1","title":"Efficacy of Low Dose Naltrexone in Psoriasis","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2019-01-01","conditions":"Psoriasis","enrollment":42},{"nctId":"NCT00817089","phase":"PHASE4","title":"Understanding Treatment Response With Naltrexone Among White Alcoholics","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-12","conditions":"Alcoholism","enrollment":24},{"nctId":"NCT00115037","phase":"PHASE4","title":"Managing Alcoholism in People Who Do Not Respond to Naltrexone","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2003-09","conditions":"Alcoholism","enrollment":302},{"nctId":"NCT00256451","phase":"PHASE4","title":"Endophenotype for Alcohol Misuse in Healthy Minority Populations","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-11","conditions":"Healthy","enrollment":43},{"nctId":"NCT02818036","phase":"NA","title":"An fMRI Study of Opioid-related Changes in Neural Activity","status":"COMPLETED","sponsor":"Tristen Inagaki","startDate":"2016-08","conditions":"Social Acceptance","enrollment":82},{"nctId":"NCT02026011","phase":"PHASE2","title":"Naltrexone for Individuals of East Asian Descent","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-12","conditions":"Alcohol Use Disorder","enrollment":87},{"nctId":"NCT01623440","phase":"","title":"Food Reward in Native American Women","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-11","conditions":"Obesity","enrollment":69},{"nctId":"NCT00663117","phase":"PHASE2","title":"The Effects of Naltrexone on Active Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-09","conditions":"Inflammation, Crohn's Disease","enrollment":40},{"nctId":"NCT00715117","phase":"PHASE2","title":"The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-07","conditions":"Crohn's Disease","enrollment":14},{"nctId":"NCT01625091","phase":"PHASE3","title":"Clinical Trial to Reduce Drinking in Women With HIV","status":"COMPLETED","sponsor":"University of Florida","startDate":"2012-12","conditions":"HIV Infection","enrollment":194},{"nctId":"NCT01993108","phase":"PHASE4","title":"Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2013-10","conditions":"Healthy, Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT01245647","phase":"PHASE2","title":"Will Having Alcohol Treatment Improve Functioning?","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-11","conditions":"HIV, Alcoholism","enrollment":19},{"nctId":"NCT00167232","phase":"PHASE3","title":"Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"1998-01","conditions":"Cocaine Dependence, Alcoholism","enrollment":164},{"nctId":"NCT01220414","phase":"NA","title":"Attenuation of Pain in Men and Women","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2010-09","conditions":"Pain","enrollment":60},{"nctId":"NCT01389167","phase":"PHASE3","title":"Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-09","conditions":"Opiate Dependence","enrollment":320},{"nctId":"NCT02317744","phase":"NA","title":"Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-12","conditions":"Binge Eating Disorder","enrollment":22},{"nctId":"NCT01057862","phase":"PHASE2","title":"Investigation of Naltrexone for Pathological Gambling","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-02","conditions":"Pathological Gambling","enrollment":9},{"nctId":"NCT01377168","phase":"PHASE4","title":"Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-05","conditions":"HIV, Alcohol Use Disorder","enrollment":159},{"nctId":"NCT00938886","phase":"PHASE2","title":"Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment","status":"COMPLETED","sponsor":"Brown University","startDate":"2009-10","conditions":"Hazardous Drinking, Cigarette Smoking","enrollment":150},{"nctId":"NCT00831272","phase":"PHASE4","title":"Pharmacogenetic Response to Naltrexone For Alcohol Dependence","status":"COMPLETED","sponsor":"David Oslin","startDate":"2009-01-05","conditions":"Alcohol Dependence","enrollment":221},{"nctId":"NCT00006489","phase":"PHASE4","title":"Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2000-12","conditions":"Alcoholism, Alcohol Dependence, Post-Traumatic Stress Disorder","enrollment":165},{"nctId":"NCT02792140","phase":"PHASE4","title":"The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams","status":"COMPLETED","sponsor":"University of Bern","startDate":"2016-03","conditions":"Neuroscience of Dreaming, Healthy","enrollment":32},{"nctId":"NCT00656630","phase":"PHASE2","title":"Medication Development in Alcoholism: Acamprosate Versus Naltrexone","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2007-12","conditions":"Alcoholism","enrollment":68},{"nctId":"NCT02206490","phase":"PHASE2","title":"Trial of Naltrexone and Dextromethorphan for Gulf War Illness","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2012-01","conditions":"Gulf War Illness","enrollment":60},{"nctId":"NCT01672723","phase":"NA","title":"Neuropharmacological Basis of Social Connection: The Role of Opioids","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-10","conditions":"Psychology, Social","enrollment":34},{"nctId":"NCT00568555","phase":"NA","title":"Effects of Low Dose Naltrexone in Fibromyalgia","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-06","conditions":"Fibromyalgia, Persian Gulf Syndrome","enrollment":53},{"nctId":"NCT02557984","phase":"NA","title":"Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-02","conditions":"Addiction","enrollment":121},{"nctId":"NCT00142909","phase":"PHASE2","title":"Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-02","conditions":"Opioid-Related Disorders","enrollment":86},{"nctId":"NCT00270231","phase":"PHASE2","title":"Effects of Naltrexone on Nicotine Reinforcement","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2004-03","conditions":"Tobacco Dependence","enrollment":64},{"nctId":"NCT01528007","phase":"PHASE4","title":"Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2011-01","conditions":"Pathological Gambling","enrollment":100},{"nctId":"NCT01296646","phase":"PHASE2","title":"Sweet Preference and Alcohol Craving","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-01","conditions":"Alcohol Dependence, Alcohol Abuse","enrollment":80},{"nctId":"NCT00768508","phase":"PHASE3","title":"Combined Pharmacotherapies for Alcoholism","status":"COMPLETED","sponsor":"Bankole Johnson","startDate":"2008-09","conditions":"Alcoholism","enrollment":300},{"nctId":"NCT00145847","phase":"PHASE4","title":"Naltrexone Treatment of Alcohol Abuse in Schizophrenia","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2003-04","conditions":"Schizophrenia, Mental Disorders, Alcohol Abuse","enrollment":90},{"nctId":"NCT01327326","phase":"NA","title":"Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2011-12","conditions":"Temporomandibular Disorder, Facial Pain","enrollment":""},{"nctId":"NCT00467558","phase":"PHASE2","title":"Double-Blind Naltrexone in Compulsive Sexual Behavior","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2007-05","conditions":"Compulsive Sexual Behavior","enrollment":7},{"nctId":"NCT00769158","phase":"PHASE1","title":"Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study","status":"COMPLETED","sponsor":"Bankole Johnson","startDate":"2008-10","conditions":"Alcoholism","enrollment":4},{"nctId":"NCT01211769","phase":"PHASE3","title":"Effects of Omegas 3 and 6 on Alcohol Dependence","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2006-02","conditions":"Alcohol Dependence","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"INJECTION SITE MASS"},{"count":1,"reaction":"MEMORY IMPAIRMENT"},{"count":1,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"}],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["naltrexone IM 380mg","Naltrexone","low dose naltrexone","Oral naltrexone","LDN"],"phase":"marketed","status":"active","brandName":"Naltrexone Pill","genericName":"Naltrexone Pill","companyName":"Albert Einstein Healthcare Network","companyId":"albert-einstein-healthcare-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for alcohol and opioids. Used for Opioid use disorder, Alcohol use disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}